ArticleAmerican journal of translational research2023
Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis.Therapeutic advances in medical oncology · 2024Article
- FBXL18 is required for ovarian cancer cell proliferation and migration through activating AKT signaling.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of mono-anlotinib therapy by itself or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer (PROC).
methodsThe clinical data of 35 patients with platinum-resistant recurrent ovarian cancer admitted to the First Affiliated Hospital of Anhui Medical University from March 2019 to July 2020 were retrospectively analyzed. All the patients received anlotinib mono- or combined chemotherapy. The effectiveness and adverse events (AEs) were analyzed by RECIST1.1 and CTCAE5.0.
resultsIn the 35 patients, the median follow-up was 9.80 (95% CI: 3.83-15.77) months. The median progression free survival (mPFS) achieved 6.50 (95% CI: 2.02-10.98) months, the objective response rate (ORR) achieved 17.14%, and disease control rate (DCR) achieved 60.00%. ORR and DCR were 12.50% and 25.0% for monotherapy, 18.52% and 70.37% for combined chemotherapy. The PFS of combined chemotherapy was longer than that of monotherapy (log-rank P = 0.003). thirty-four patients (97.14%) were in a third-line therapy or above, and their ORR and DCR were 14.71% and 58.82%, respectively. Two patients discontinued treatment because of intolerable AEs. No cases of grade 4-5 AEs have been reported.
conclusionAnlotinib had promising effectiveness and tolerable safety in patients with PROC, even in patients who accepted anlotinib as a third-line or above therapy or with a history of other antiangiogenic drugs.
Indexed as
Identifiers
37056822PMC10086922W4365479093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.